Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.38 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349403 | 1.00 | CRBN (0.39) | CRBNSIGMAR1KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL26090703 | 0.93 | CRBN (0.39) | CRBNSIGMAR1GSPT1DDB1LMNA | |
| SCHEMBL26090582 | 0.93 | LMNA (0.45) | CRBNSIGMAR1GSPT1DDB1LMNA | |
| SCHEMBL30349469 | 0.92 | CRBN (0.47) | CRBNSIGMAR1GSPT1DDB1 | |
| SCHEMBL26090483 | 0.92 | CRBN (0.47) | CRBNSIGMAR1GSPT1DDB1 | |
| SCHEMBL30349374 | 0.92 | SIGMAR1 (0.44) | CRBNSIGMAR1GSPT1DDB1LMNA | |
| SCHEMBL26089109 | 0.92 | SIGMAR1 (0.44) | CRBNSIGMAR1GSPT1DDB1LMNA | |
| SCHEMBL26089622 | 0.91 | CRBN (0.41) | CRBNSIGMAR1GSPT1DDB1LMNA | |
| SCHEMBL30349614 | 0.90 | EPHX2 (0.47) | CRBNSIGMAR1DDB1LMNAEPHX2 | |
| SCHEMBL26089592 | 0.90 | EPHX2 (0.47) | CRBNSIGMAR1DDB1LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069731-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294495-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CRBN, GSPT1, GSPT2 | CRBN 1/4885SIGMAR1 3933/4885KCNJ6 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.